HOME >> MEDICINE >> NEWS
Yale prostate cancer study shows newer implant therapy has fewer side-effects, could lead to better treatment outcomes

New Haven, Conn. -- A Yale study of complication rates from two radiation implant therapies for prostate cancer shows that the newer therapy, Palladium-103, has fewer long-term side effects than Iodine-125, an older, more commonly prescribed therapy.

"While both implants were extraordinarily successful at preventing major long-term complications, Palladium-103 was superior to Iodine-125 in preventing moderate long-term complications by 13 percent," said Richard Peschel, M.D., professor of therapeutic radiology at Yale School of Medicine. "Our study is the first to compare prostate cancer implant therapies, and the results could lead to improved outcomes for patients."

In the seven-year study, Peschel and his team also found that the minimum dose for Palladium-103 could be increased without increasing side effects. This increased dose has the potential for improving cure rates, Peschel says.

Published in the Oct. 29 issue of Radiation Oncology Investigations: Clinical and Basic Research, the findings are significant for men facing a treatment decision for prostate cancer.

When diagnosed with prostate cancer, most men are presented with two treatment options: radical surgery and implant therapy, which involves placing 75 to 100 small radioactive seeds throughout the prostate using a one-time, minimally invasive procedure. Implant therapy is an increasingly popular choice because it is a cheaper, simpler out-patient procedure that involves far less recovery time, a lower complication rate and cure rates that are equivalent to radical surgery.

For 10 to 15 years, Iodine-125 was the most frequently prescribed implant treatment, but newer therapies have emerged, including Palladium-103. Prostate cancer implant programs using either Iodine-125 or Palladium-103 radioactive seeds have been extremely successful in treating early prostate cancer. About 30,000 prostate implants will be performed in the United States in the year 2000.

The resear
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
28-Oct-1999


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Cultural and social factors influence prostate cancer treatment
3. Earlier use of prostate cancer vaccines urged by Hopkins scientists
4. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
5. Men more likely to get screened for prostate cancer than colon cancer, U-M study finds
6. Mayo Clinic identifies key cellular process in prostate and other cancers
7. Obesity may affect accuracy of prostate screening
8. More precise radiation therapy lets prostate cancer patients avoid erectile dysfunction
9. Combining hormones with external, internal radiation helps high risk prostate cancer patients
10. Silent risk of osteoporosis in men with prostate cancer
11. NIH launches new study to compare prostate surgery and drugs

Post Your Comments:
(Date:10/31/2014)... In an effort to expand services and improve efficiency ... will soon offer orthodontics at his Oral & Maxillofacial Surgery ... , To build upon the high degree of care and ... known for, Dr. Jamali is welcoming an orthodontist that is ... as UCLA, Stanford and UCSF. He added that the new ...
(Date:10/31/2014)... 2014 Phoenix dentist , Dr. Christy, ... November. Whether patients simply need routine care or have a ... than now to get that necessary care. The right dental ... routine and even essential treatments due to financial concerns. Throughout ... on any treatments offered by the team at Christy Dental ...
(Date:10/31/2014)... Uniwigs.com newly arrived flip in hair extensions are ... itself around people’s heads with a transparent miracle wire undetectable ... comes with adjustable loops, which are improved over the basic ... now adjust the wire to best fit the size of ... generation of flip ins, they simply need to adjust the ...
(Date:10/31/2014)... 31, 2014 Med-Care Diabetic & Medical ... highest principles of patient care and service, announced a ... and wellness website, to provide an online Diabetes ... , The Diabetes Health Center will provide topical information ... living with diabetes. Content will feature advice from leading ...
(Date:10/31/2014)... FRIDAY, Oct. 31, 2014 (HealthDay News) -- A few simple ... cope with, a sleep expert says. "Adjusting to the ... bit easier than handling the time change in the spring. ... sleep for the fall time change," Dr. Praveen Rudraraju, director ... in Mount Kisco, N.Y., said in a hospital news release. ...
Breaking Medicine News(10 mins):Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2Health News:UniWigs Unveiles New Generation of Flip In Hair Extensions 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 3Health News:Make the Most of This Weekend's Time Change 2
(Date:10/31/2014)... 31, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug ... a conference call to discuss the clinical results ... the company,s proprietary oral insulin capsules, to treat ... at 10:00 a.m. Eastern time. Shareholders ...
(Date:10/31/2014)... 31, 2014 Investor-Edge has initiated ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow ...
(Date:10/31/2014)... 3, 2014 British Journal ... BPH to discuss "male orgasmic dysfunction" with their doctor ... treat prostate symptoms while preserving sexual function   ... publication of a paper in the British Journal of ... prostate to discuss with their doctors the likely impact ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2
Cached News: